LLNL 3D Protein-Ligand Dataset for Anti-viral Screening against SARS-CoV-2. In Lawrence Livermore National Laboratory (LLNL) Open Data Initiative

This dataset contains protein-ligand complexes in a 3D representation for anti-viral drug screening against SARS-CoV-2. This is a part of the Lawrence Livermore National Laboratory Covid-19 Therapeutic Design database, but is specifically designed to facilitate machine learning and other data science tasks with regard to both efficacy (protein-ligand binding affinity) and safety. This complex dataset is called "ml-hdf", comprised of ligands and four potential binding pockets of the SARS-CoV-2 protein targets in a 3D atomic representation. The ligands in this dataset includes Federal Drug Administration (FDA) approved drugs and "Other-world-approved" drugs that have been approved for use by the EU, Canada and Japan. The compounds were docked against two binding pockets from the Spike protein (spike, spike1) and two conformations of the main protease (protease, protease2).